Polaryx Therapeutics (PLYX) Q4 2025 earnings summary

Executive summary

• Clinical-stage biotech focused on novel therapies for rare pediatric lysosomal storage disorders (LSDs), with a multi-modal pipeline including small molecules and gene therapy.

• Lead candidate PLX-200 is advancing to a Phase 2 basket trial (SOTERIA) targeting multiple LSDs, with IND clearance and trial initiation expected in the second half of 2026.

• No product revenue to date; operations funded primarily through equity issuances totaling $21.7 million since inception.

Financial highlights

• Net loss for 2025 was $9.0 million, a significant improvement from $30.4 million in 2024, primarily due to the absence of a $26.0 million recapitalization expense recorded in 2024.

• Research and development expenses increased to $6.3 million in 2025 from $2.8 million in 2024, driven by consulting, CRO services, and stock-based compensation.

• General and administrative expenses were stable at $1.5 million year-over-year.

• Cash and cash equivalents as of December 31, 2025 were $5.1 million, with no outstanding debt.

• Accumulated deficit reached $99.6 million as of year-end 2025.

Outlook and guidance

• Existing cash is expected to fund operations through Q3 2026; additional capital will be required for continued operations and clinical development beyond that period.

• Management anticipates increased expenses as clinical programs advance and as the company operates as a public entity.